The Influence of Membrane Molecular Weight Cutoff on a Novel Bioartificial Liver
Yue Zhang
Department of Hepatobiliary Surgery, Drum Tower Clinical Medical College of Nanjing Medical University
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorXiao-lei Shi
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorBing Han
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorJin-yang Gu
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorXue-hui Chu
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorJiang-qiang Xiao
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorHao-zhen Ren
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorJiao-jun Tan
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorCorresponding Author
Yi-tao Ding
Department of Hepatobiliary Surgery, Drum Tower Clinical Medical College of Nanjing Medical University
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Dr. Yi-Tao Ding, Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing 210008, China. E-mail: [email protected]Search for more papers by this authorYue Zhang
Department of Hepatobiliary Surgery, Drum Tower Clinical Medical College of Nanjing Medical University
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorXiao-lei Shi
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorBing Han
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorJin-yang Gu
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorXue-hui Chu
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorJiang-qiang Xiao
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorHao-zhen Ren
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorJiao-jun Tan
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Search for more papers by this authorCorresponding Author
Yi-tao Ding
Department of Hepatobiliary Surgery, Drum Tower Clinical Medical College of Nanjing Medical University
Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing, China
Dr. Yi-Tao Ding, Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing 210008, China. E-mail: [email protected]Search for more papers by this authorAbstract
Given the xenogeneic immune reaction relevant to the molecular weight cutoff of the membrane of a bioartificial liver (BAL) system, we investigated the influence of membrane molecular weight cutoff in our BAL system in this study. Acute liver failure in beagles was induced by d-galactosamine administration. Eight beagles were divided into two groups by the membrane molecular weight cutoff of the plasma component separator. Group 1 beagles were treated with BAL containing 200 kDa retention rating membrane. Group 2 beagles were treated with BAL containing 1200 kDa retention rating membrane. Each group underwent two 6-h BAL treatments that were performed on day 1 and day 21. The hemodynamic and hematologic response, humoral immune responses, and cytotoxic immune response to BAL therapy were studied before and after treatments. All beagles remained hemodynamically and hematologically stable during BAL treatments. BAL treatment was associated with a significant decline in levels of complement; however, a longer time of level maintenance was observed in Group 2. Group 2 beagles experienced a significant increase in levels of IgG and IgM after two BAL treatments. Significant levels of canine proteins were detected in BAL medium from Group 2; only trace levels of canine proteins were detected in BAL medium from Group 1. The posttreatment viability of co-culture cells in Group 2 was lower compared with Group 1, and the viability of co-culture cells after treatments was associated with deposition of canine proteins on the cells. Xenogeneic immune response was influenced by membrane molecular weight cutoff in the BAL.
REFERENCES
- 1 Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010; 376: 190–201.
- 2 Starzl TE, Fung JJ. Themes of liver transplantation. Hepatology 2010; 51: 1869–84.
- 3 Kinasiewicz A, Gautier A, Lewiska D, Smietanka A, Legallais C, Weryński A. Three-dimensional growth of human hepatoma C3A cells within alginate beads for fluidized bioartificial liver. Int J Artif Organs 2008; 31: 340–7.
- 4 Poyck PP, van Wijk AC, van der Hoeven TV, et al. Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver. J Hepatol 2008; 48: 266–75.
- 5 Poyck PP, Hoekstra R, van Wijk AC, et al. Functional and morphological comparison of three primary liver cell types cultured in the AMC bioartificial liver. Liver Transpl 2007; 13: 589–98.
- 6 Chamuleau RA, Deurholt T, Hoekstra R. Which are the right cells to be used in a bioartificial liver? Metab Brain Dis 2005; 20: 327–35.
- 7 Rikker C. Liver support systems today. Orv Hetil 2009; 150: 2299–307.
- 8 Chamuleau RA, Poyck PP, van de Kerkhove MP. Bioartificial liver: its pros and cons. Ther Apher Dial 2006; 10: 168–74.
- 9 Ding YT, Qiu YD, Chen Z, et al. The development of a new bioartificial liver and its application in 12 acute liver failure patients. World J Gastroenterol 2003; 9: 829–32.
- 10 Chen Z, Ding YT. Functional evaluation of a new bioartificial liver system in vitro and in vitro. World J Gastroenterol 2006; 12: 1312–6.
- 11 Talbot NC, Caperna TJ, Willard RR, Meekin JH, Garrett WM. Characterization of two subpopulations of the PICM-19 porcine liver stem cell line for use in cell-based extracorporeal liver assistance devices. Int J Artif Organs 2010; 33: 348–61.
- 12 Maringka M, Giri S, Bader A. Preclinical characterization of primary porcine hepatocytes in a clinically relevant flat membrane bioreactor. Biomaterials 2010; 31: 156–72.
- 13 Nedredal GI, Amiot BP, Nyberg P, et al. Optimization of mass transfer for toxin removal and immunoprotection of hepatocytes in a bioartificial liver. Biotechnol Bioeng 2009; 104: 995–1003.
- 14 Baquerizo A, Mhoyan A, Shirwan H, et al. Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver. Transplant Proc 1997; 29: 964–5.
- 15 Nyberg SL, Amiot B, Hardin J, Baskin-Bey E, Platt JL. Cytotoxic immune response to a xenogeneic bioartificial liver. Cell Transplant 2004; 13: 783–91.
- 16 Matsushita T, Amiot B, Hardin J, Platt JL, Nyberg SL. Membrane pore size impacts performance of a xenogeneic bioartificial liver. Transplantation 2003; 76: 1299–305.
- 17 Nyberg SL, Yagi T, Matsushita T, et al. Membrane barrier of a porcine hepatocyte bioartificial liver. Liver Transpl 2003; 9: 298–305.
- 18 Gu J, Shi X, Chu X, Zhang Y, Ding Y. Contribution of bone marrow mesenchymal stem cells to porcine hepatocyte culture in vitro. Biochem Cell Biol 2009; 87: 595–604.
- 19 Gu J, Shi X, Zhang Y, Chu X, Hang H, Ding Y. Establishment of a three-dimensional co-culture system by porcine hepatocytes and bone marrow mesenchymal stem cells in vitro. Hepatol Res 2009; 39: 398–407.
- 20 Nedredal GI, Amiot BP, Nyberg P, et al. Optimization of mass transfer for toxin removal and immunoprotection of hepatocytes in a bioartificial liver. Biotechnol Bioeng 2009; 104: 995–1003.
- 21 Galili U, Gregory CR, Morris RE. Contribution of anti-Gal to primate and human IgG binding to porcine endothelial cells. Transplantation 1995; 60: 210–3.
- 22 Nara M, Hakamada K, Totsuka E, Nozaki T, Takiguchi M, Sasaki M. Efficacy of double filtration plasmapheretic cross-circulation using a high permeability membrane between totally hepatectomized dogs and donor pigs. Transplantation 2001; 72: 1736–42.
- 23 Baquerizo A, Mhoyan A, Kearns-Jonker M, et al. Characterization of human xenoreactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment: an ex vivo model of pig to human xenotransplantation. Transplantation 1999; 67: 5–18.
- 24 Ohgawara H, Hirotani S, Miyazaki J, Teraoka S. Membrane immunoisolation of a diffusion chamber for bioartificial pancreas. Artif Organs 1998; 22: 788–94.
- 25 Nakaya Y, Shojima T, Yasuda J, Miyazawa T. Unusual permeability of porcine endogenous retrovirus subgroup A through membrane filters. J Vet Med Sci 2010; 72: 67–71.
- 26 Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 1977; 296: 769–74.
Citing Literature
